series-c-plus
Stage
2015
Founded
5
Investors
About
TScan Therapeutics develops anti-tumor T cell receptors (TCRs) by identifying their antigens through a genome-wide high-throughput platform, enabling new immuno-oncology treatments for patients not served by current cancer therapies.
Explore TScan Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.